Effect of beraprost on pulmonary hypertension due to left ventricular systolic dysfunction

Abstract

Beraprost is used to treat peripheral chronic arterial occlusive disease. However, the efficacy and safety of beraprost in patients with pulmonary hypertension (PH) due to left ventricular systolic dysfunction (PH-HFrEF) remains unknown. The primary objective of this study was to determine the effects of beraprost on PH-HFrEF. We prospectively recruited patients with PH-HFrEF as determined by echocardiography and right cardiac catheterization. Beraprost sodium was given orally (1mg/kg/d) added to the usual treatment, and patients were evaluated at 1-year follow-up. Twenty-five patients were recruited with baseline systolic pulmonary artery pressure (PAP) of 49.5±10.8mm Hg. Systolic PAP results at 3, 6, 9, and 12 months were 39.1±8.1, 30.4±5.2, 27.7±3.0, and 27.0±4.7mm Hg, respectively, which were all significantly lower than systolic PAP at baseline (P